A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study.

[1]  J. Heitman,et al.  Faculty Opinions recommendation of Genome-wide maps of recombination and chromosome segregation in human oocytes and embryos show selection for maternal recombination rates. , 2016 .

[2]  J. Delotte,et al.  Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of endometrial cancer with peritoneal carcinomatosis. , 2014, European journal of obstetrics, gynecology, and reproductive biology.

[3]  P. Fracasso,et al.  A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. , 2012, Gynecologic oncology.

[4]  D. Miller,et al.  Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study , 2012 .

[5]  P. Fracasso,et al.  A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. , 2012, Gynecologic oncology.

[6]  B. Monk,et al.  Incorporation of bevacizumab in the primary treatment of ovarian cancer. , 2011, The New England journal of medicine.

[7]  R. Barakat,et al.  Surgical cytoreduction in stage IV endometrioid endometrial carcinoma. , 2011, Gynecologic oncology.

[8]  M. Morgan,et al.  A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. , 2011, Gynecologic oncology.

[9]  R. Barakat,et al.  Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  T. Jobo,et al.  Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial , 2009, The Lancet.

[11]  D. Alberts,et al.  Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  L. Landrum,et al.  Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis. , 2009, Gynecologic oncology.

[13]  Joan L. Walker,et al.  Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Burger,et al.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer. , 2006, The New England journal of medicine.

[15]  J. Thigpen,et al.  Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Burger,et al.  Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. N. Coleman,et al.  CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. , 2003, Seminars in radiation oncology.

[18]  M. J. Webb,et al.  Endometrial cancer: predictors of peritoneal failure. , 2003, Gynecologic oncology.

[19]  M. J. Webb,et al.  Stage IIIC endometrioid corpus cancer includes distinct subgroups. , 2002, Gynecologic oncology.

[20]  R. Mannel,et al.  Analysis of FIGO Stage IIIc endometrial cancer patients. , 2001, Gynecologic oncology.

[21]  B N Bundy,et al.  Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  F. Montz,et al.  Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. , 2000, Gynecologic oncology.

[23]  G. Sutton,et al.  FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy. , 1999, Gynecologic oncology.

[24]  Y. Taketani,et al.  Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy. , 1997, British Journal of Cancer.

[25]  B. Bundy,et al.  Surgical pathologic spread patterns of endometrial cancer: A gynecologic oncology group study , 1987, Cancer.